Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Common Stock · Q3 FY2026 · quarter ended Sep 2026

Common stock rises 11.7% from a year ago

Common stock stood at $143K at the end of Q3 FY2026, up 11.7% from a year earlier and up 0.7% from the prior quarter. Over 3 fiscal years it compounded at +28.7% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +11.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$143K+0.7% QoQ
Last fiscal yearDec 2025
$128K+36.2% YoY
Year agoSep 2025
$128K+11.7% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.7%——
1 year+36.2%——
3-year CAGR+28.7%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
128K USD
Year-over-year change
+36.2%
4-year CAGR
+44.9%

Common Stock vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +11.7% is the 3rd highest of 7, against a peer median of +3.3%.
  • Common stock amounts to 0.0% of total assets for TRVI, versus a peer median of 0.0%.
TRVI Competitors
Common Stock for TRVI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VCREVicore Pharma Holding ABJun 2026SEK 88.04M SEK——91.8%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$426K USD+16.4%+24.6%0.2%
TRVITrevi Therapeutics, Inc.Sep 2026$143K USD+11.7%+28.7%0.0%
LQDALiquidia CorporationJun 2026$89K USD+4.7%+10.8%0.0%
UPBUpstream Bio, Inc.Mar 2026$54K USD+1.9%+162.1%0.0%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$48K USD+29.7%+15.7%0.0%
TENXTenax Therapeutics, Inc.Mar 2026$2K USD—-39.8%0.0%
TBPHTheravance Biopharma, Inc.Mar 2026$1K USD+0.0%+0.0%0.0%
ACADACADIA Pharmaceuticals Inc.Sep 2026$0 USD-100.0%+0.0%0.0%
Peer median (excluding TRVI) —+3.3%+10.8%0.0%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents36.83M12.59M32.4M34.1M18.91M
Short-term Investments0107.92M50.57M73.53M169.35M
Net Receivables241K00532K986K
Inventory00000
Other Current Assets01.31M955K335K1.15M
Total Current Assets37.96M122.62M87.55M109.43M191.66M
Property, Plant & Equipment (Net)184K194K1.56M1.23M855K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets334K205K297K243K928K
Total Non-current Assets518K399K1.86M1.47M1.78M
Total Assets38.48M123.02M89.4M110.9M193.44M
Account Payables2.85M2.86M1.81M3.41M3.91M
Short-term Debt5.83M7M000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities114K1.51M1.61M2.54M2.75M
Total Current Liabilities12.72M13.4M5.82M10.51M9.75M
Long-term Debt8.65M2.15M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities03K000
Total Non-current Liabilities8.68M2.16M1.03M747K446K
Total Liabilities21.4M15.56M6.86M11.26M10.2M
Common Stock29K60K68K94K128K
Retained Earnings(180.92M)(210.07M)(239.13M)(287.05M)(329.8M)
Accumulated OCI0(122K)(29K)61K148K
Other Stockholders Equity00000
Minority Interest00000
Total Equity17.08M107.46M82.55M99.64M183.24M
Total Debt14.63M9.18M1.34M1.03M753K
Net Debt(22.2M)(3.41M)(31.06M)(33.07M)(18.16M)

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.